Javascript must be enabled to continue!
Liver Fibrosis: From Basic Science to Clinical Progress
View through CrossRef
The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts, lose their vitamin A, upregulate -smooth muscle actin, and produce pro-inflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.
Title: Liver Fibrosis: From Basic Science to Clinical Progress
Description:
The burden of chronic liver disease is globally increasing at an alarming rate.
Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer and mortality.
LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs).
In the healthy liver, quiescent HSCs metabolize and store retinoids.
Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts, lose their vitamin A, upregulate -smooth muscle actin, and produce pro-inflammatory soluble mediators, collagens, and inhibitors of ECM degradation.
Activated HSCs are the main effector cells during hepatic fibrogenesis.
In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival.
The main source of myofibroblasts is resident HSCs.
Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar.
Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous.
The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators.
Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines.
Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis.
Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells.
However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive.
This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.
Related Results
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
Modern Principles of Liver Fibrosis Diagnosis in Patients With Chronic Diffuse Liver Lesions: Literature Review and Clinical Case Description
Modern Principles of Liver Fibrosis Diagnosis in Patients With Chronic Diffuse Liver Lesions: Literature Review and Clinical Case Description
Introduction. Chronic diffuse liver lesions, which is at a certain stage and phase of the disease characterized by excessive accumulation of components of the extracellular matrix,...
B-268 Proteo-transcriptomics Analysis Reveals Novel Diagnostic Biomarkers for Liver Fibrosis
B-268 Proteo-transcriptomics Analysis Reveals Novel Diagnostic Biomarkers for Liver Fibrosis
Abstract
Background
Early diagnosis and prompt intervention are crucial for the effective management of liver fibrosis. Currentl...
Expression of LINC00963 in Preoperative Liver Tissues of Biliary Atresia and Its Correlation with Postoperative Liver Fibrosis Progression
Expression of LINC00963 in Preoperative Liver Tissues of Biliary Atresia and Its Correlation with Postoperative Liver Fibrosis Progression
Abstract
Objective:
To investigate the expression level of long non-coding RNA (lncRNA) LINC00963 in preoperative liver tissues...
Initial study of biexponential model of intravoxel incoherent motion magnetic resonance imaging in evaluation of the liver fibrosis
Initial study of biexponential model of intravoxel incoherent motion magnetic resonance imaging in evaluation of the liver fibrosis
Background
The diagnosis of liver fibrosis is a difficult task at any time using conventional clinical imaging. Intravoxel incoherent motion (IVIM) can be used to inves...
Effect of Qizhu Granule on Liver Sinusoidal Endothelial Cells Capillarization in Carbon Tetrachloride-Induced Rats Fibrosis.
Effect of Qizhu Granule on Liver Sinusoidal Endothelial Cells Capillarization in Carbon Tetrachloride-Induced Rats Fibrosis.
Abstract
Background: Qizhu granule, a traditional Chinese medicine, has been widely used in clinic as a complementary and alternative medicine to treat liver fibrosis.Howev...
Prevalence of high-risk for advanced liver fibrosis using non-invasive scores among type 2 diabetes mellitus patients in the United Arab Emirates: a retrospective cross-sectional study
Prevalence of high-risk for advanced liver fibrosis using non-invasive scores among type 2 diabetes mellitus patients in the United Arab Emirates: a retrospective cross-sectional study
Background
Advanced liver fibrosis is a major determinant of liver-related morbidity and mortality and occurs more frequently in individuals with type 2 diabete...

